Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOGNASDAQ:ALECNASDAQ:ATHENASDAQ:INMB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$9.21-3.8%$7.90$3.75▼$11.40$153.31M2.7990,607 shs86,149 shsALECAlector$1.50+0.7%$1.30$0.87▼$6.78$148.99M0.71834,992 shs362,911 shsATHEAlterity Therapeutics$3.92+2.1%$4.15$1.00▼$5.87$34.09M0.8144,307 shs90,255 shsINMBINmune Bio$6.28-14.8%$7.46$4.32▼$10.50$169.39M1.55339,469 shs3.54 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition+7.65%+7.05%+4.70%+80.23%+956,999,900.00%ALECAlector0.00%+2.05%+20.16%+12.03%-65.83%ATHEAlterity Therapeutics-13.22%-11.52%-9.65%+7.87%+113.93%INMBINmune Bio+11.50%+1.80%+0.96%-0.54%+3.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACOGAlpha Cognition1.2175 of 5 stars3.50.00.00.00.60.80.0ALECAlector3.5232 of 5 stars3.11.00.04.51.82.50.0ATHEAlterity Therapeutics1.4871 of 5 stars3.33.00.00.00.01.70.0INMBINmune Bio2.186 of 5 stars3.60.00.00.03.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$20.00117.16% UpsideALECAlector 2.14Hold$4.00166.67% UpsideATHEAlterity Therapeutics 2.50Moderate Buy$12.00206.12% UpsideINMBINmune Bio 3.17Buy$22.80263.06% UpsideCurrent Analyst Ratings BreakdownLatest ATHE, ALEC, ACOG, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/31/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha CognitionN/AN/AN/AN/A$2.59 per shareN/AALECAlector$100.56M1.49N/AN/A$1.29 per share1.16ATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/AINMBINmune Bio$10K14,431.44N/AN/A$1.45 per share4.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$14.64M-$1.20N/A∞N/AN/A-65.83%-48.21%8/11/2025 (Estimated)ALECAlector-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)ATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/A8/4/2025 (Estimated)INMBINmune Bio-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)Latest ATHE, ALEC, ACOG, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ACOGAlpha Cognition-$0.58-$0.20+$0.38-$0.13$0.50 million$2.93 million5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 million3/31/2025Q4 2024ACOGAlpha Cognition-$0.48-$0.51-$0.03-$0.51N/AN/A3/27/2025Q4 2024INMBINmune Bio-$0.54-$0.40+$0.14-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AALECAlectorN/AN/AN/AN/AN/AATHEAlterity TherapeuticsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A17.1416.83ALECAlector0.103.343.34ATHEAlterity TherapeuticsN/A3.84N/AINMBINmune BioN/A2.642.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AALECAlector85.83%ATHEAlterity Therapeutics2.14%INMBINmune Bio12.72%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%ALECAlector9.10%ATHEAlterity Therapeutics38.80%INMBINmune Bio35.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A16.02 million13.78 millionN/AALECAlector27099.99 million90.89 millionOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableINMBINmune Bio1022.98 million14.78 millionOptionableATHE, ALEC, ACOG, and INMB HeadlinesRecent News About These CompaniesINmune Bio Climbs on Plan to Report Alzheimer's Study Data Monday1 hour ago | marketwatch.comLas acciones de INmune Bio se disparan antes de la publicación de datos sobre AlzheimerJune 26 at 6:50 PM | es.investing.comINmune Bio put volume heavy and directionally bearishJune 26 at 6:50 PM | msn.comINmune Bio stock soars ahead of Alzheimer’s trial data releaseJune 26 at 6:50 PM | za.investing.comINmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30thJune 26 at 6:50 PM | finance.yahoo.comINmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30thJune 26 at 4:00 PM | globenewswire.comINmune Bio Target of Unusually Large Options Trading (NASDAQ:INMB)June 21, 2025 | americanbankingnews.comINmune Bio Target of Unusually High Options Trading (NASDAQ:INMB)June 20, 2025 | marketbeat.comINmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative OpportunityJune 16, 2025 | seekingalpha.comINmune Bio, Inc. Collaborates on Study Showing XPro™ Treatment Reduces Alzheimer’s-like Pathology After Traumatic Brain Injury in MiceJune 12, 2025 | nasdaq.comINmune Bio, Inc. (NASDAQ:INMB) Shares Bought by Two Sigma Investments LPJune 11, 2025 | marketbeat.comMillennium Management LLC Boosts Stake in INmune Bio, Inc. (NASDAQ:INMB)June 4, 2025 | marketbeat.comINmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big OpportunityMay 15, 2025 | seekingalpha.comINmune Bio, Inc. (INMB) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comINmune Bio appoints new accounting firmMay 9, 2025 | investing.comINmune Bio, Inc.: INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business UpdateMay 9, 2025 | finanznachrichten.deINmune Bio Inc. Announces First Quarter 2025 Results and Provides Business UpdateMay 8, 2025 | globenewswire.comINmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8thMay 5, 2025 | globenewswire.comINmune Bio to receive US patent for next-generation mesenchymal stromal cell product, CORDStromApril 19, 2025 | pharmabiz.comPINmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform TechnologyApril 16, 2025 | markets.businessinsider.comINmune Bio receives favorable patentability opinion for CORDStrom platformApril 16, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATHE, ALEC, ACOG, and INMB Company DescriptionsAlpha Cognition NASDAQ:ACOG$9.21 -0.36 (-3.76%) As of 04:00 PM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Alector NASDAQ:ALEC$1.50 +0.01 (+0.67%) Closing price 04:00 PM EasternExtended Trading$1.52 +0.02 (+1.60%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Alterity Therapeutics NASDAQ:ATHE$3.92 +0.08 (+2.08%) Closing price 04:00 PM EasternExtended Trading$4.10 +0.18 (+4.57%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.INmune Bio NASDAQ:INMB$6.28 -1.09 (-14.79%) Closing price 04:00 PM EasternExtended Trading$11.18 +4.90 (+78.04%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
